Date: 2011-10-04
Type of information: Production agreement
Compound: Newcastle Disease Virus (NDV) produced on Vivalis EB66® cell line
Company: Vivalis (France) Delta-Vir (Germany)
Therapeutic area: Cancer - Oncology - Infectious diseases
Type agreement: commercialisation
production
manufacturing
Action mechanism:
Disease:
Details: Vivalis and Delta-Vir have entered into a commercial agreement to manufacture GMP grade material of Newcastle Disease Virus (NDV) produced on Vivalis EB66® cell line. This is a first step of a broader collaboration between the companies to develop an EB66®-based production process of purified NDV virus and to manufacture clinical grade NDV to be used in conjunction with a cell based anti-tumour vaccine for therapeutic treatment of different human neoplasms. Delta-Vir has developed a unique immunotherapy incorporating non-human pathogenic oncolytic NDV. This immunotherapy has already been administered to patients as a compassionate anti-cancer treatment in Germany. Because of the promising results obtained so far with over 600 patients, Delta-Vir wishes to provide this promising treatment to a larger population of patients and it is seeking to get regulatory approval. To do so, Delta-Vir and Vivalis will partner to develop and validate a GMP grade process of production of NDV virus to be compliant with regulatory requirements. Delta-Vir intends to file an IND for an orphan drug-status cancer immunotherapy as soon as 2013.
Financial terms: Financial terms were not disclosed.
Latest news:
